Pharma BD Deal Intelligence
$4.25/share cash plus CPRs of up to $4.50/share contingent on ADL5945 FDA/EMA approval by July 2019 and competitive labeling — the structure transferred…
Industry observers said the deal could stimulate broader interest in OIC, and that Cubist's hospital sales force was well-suited to commercialize Entereg into…
By 2014 Entereg US revenue had grown 17.6% YoY to $43.8M through nine months, and the asset was a contributing piece of Merck's $9.5B Cubist acquisition that…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Cubist acquired Adolor for $4.25/share (~$190M cash) plus CPRs of up to $4.50/share tied to ADL5945 milestones, total up to $415M. Deal added marketed Entereg and a Phase 2 OIC candidate to Cubist's hospital franchise.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cubist Pharmaceuticals, Inc. / Adolor Corporation (this deal) | 2011 | $415M | 49 |
| Cubist Pharmaceuticals, Inc. / Calixa Therapeutics, Inc. | 2009 | $402M | 52 |
| Cubist Pharmaceuticals, Inc. / Optimer Pharmaceuticals, Inc. | 2013 | $801M | 45 |
| Cubist Pharmaceuticals, Inc. / Trius Therapeutics Inc. | 2013 | $707M | 44 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
← Browse all deals · How we score deals
More: 2011 deals · Cubist Pharmaceuticals, Inc. deals · Gastroenterology deals